### Guideline Page and Request

**INTERNAL REQUEST:**
In response to the FDA approval of the additional pembrolizumab dose/administration option of 400 mg every 6 weeks, the panel voted on this pembrolizumab dose/administration option.

**EXTERNAL REQUEST:**
Submission from Merck & Co., Inc., to request the inclusion of the updated dosing recommendations for pembrolizumab, either 200 mg every 3 weeks or 400 mg every 6 weeks administered as a 30-minute intravenous (IV) infusion until disease progression, unacceptable toxicity, or up to 24 months for the treatment of adult patients with microsatellite instability-high (MSI-H) breast cancer, to BINV-R (page 2 of 3) in the NCCN Breast Cancer Guidelines.

### Panel Discussion/References
Based on a review of data and the recent FDA approval, the panel consensus was to include the additional pembrolizumab dose/administration option: 400 mg IV on day 1, every 6 weeks until disease progression or unacceptable toxicity, or up to 24 months.

**Reference:**

### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>0</td>
<td>0</td>
<td>11</td>
</tr>
</tbody>
</table>